SCHEMBL25228564

SCHEMBL25228564

Clc1nc(COC2CCCCO2)ccc1Br

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ICAM1 P05362 1/20 0.33
SELE P16581 1/20 0.33
MBOAT4 Q96T53 1/20 0.33
CCNA2 P20248 1/20 0.32
CDK2 P24941 1/20 0.32
CCNA1 P78396 1/20 0.32
CDK5 Q00535 1/20 0.32
CDK5R1 Q15078 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CEL P19835 1/20 0.31
P2RX3 P56373 5/20 0.31
DHFR P00374 1/20 0.31
CREBBP Q92793 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30486438 1.00 KDM4C (0.43) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL17878832 0.85 KDM4C (0.43) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL11090556 0.81 KDM4C (0.46) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL3889222 0.81 KDM4C (0.46) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL19715580 0.79 KDM4C (0.41) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL15640169 0.78 KDM4C (0.45) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL9261561 0.78 KDM4C (0.46) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL23531793 0.78 KDM4C (0.43) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL15278408 0.78 ICAM1 (0.39) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL31394558 0.77 NOS3 (0.38) KDM4CL3MBTL1NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282782-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS GENZYME CORP (US) 2025-09-11 US disclosed
EP-4448526-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS GENZYME CORPORATION (US) 2024-10-23 EP disclosed
EP-4227307-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS Genzyme Corporation (US) 2023-08-16 EP disclosed
WO-2023114954-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS GENZYME CORPORATION (US) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282782-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS PTPN5, PTPN2, PTPRJ KDM4C 1831/4885L3MBTL1 3713/4885NPC1 3344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.